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To characterize the distribution of nontuberculous 
mycobacteria (NTM) species isolated from pulmonary 
samples from persons in Asia and their association 
with pulmonary infections, we reviewed the literature. 
Mycobacterium avium complex bacteria were most 
frequently isolated (13%–81%) and were the most common 
cause of pulmonary NTM disease (43%–81%). Also 
pathogenic were rapidly growing mycobacteria (M. chelonae, 
M. fortuitum, M. abscessus). Among all NTM isolated from 
pulmonary samples, 31% (582/1,744) were considered 
clinically relevant according to American Thoracic Society 
diagnostic criteria. Most patients were male (79%) and had 
a history of tuberculosis (37%). In Asia, high prevalence of 
rapidly growing mycobacteria and a history of tuberculosis 
are distinct characteristics of pulmonary NTM disease. This 
geographic variation is not well reﬂ  ected in the American 
Thoracic Society criteria for NTM infections and could be 
incorporated in future guidelines.
N
ontuberculous mycobacteria (NTM) are common in 
the environment and have been isolated worldwide (1). 
They are increasingly recognized as pathogens in humans. 
Pulmonary disease is the most common manifestation (2) 
and is thought to result from aerosol inhalation. Because of 
their omnipresence in the environment, isolation of NTM 
from the respiratory tract does not, per se, indicate NTM 
disease. Therefore, the American Thoracic Society (ATS) 
has established diagnostic criteria to help distinguish 
between contamination and true NTM disease (1).
Although NTM are present worldwide, much of 
the literature on pulmonary NTM disease comes from 
industrialized countries, mainly Europe, North America, 
and Japan. Differences in the NTM species distribution in 
clinical samples and disease have been noted among these 
regions (3); by extrapolation, these characteristics in other 
parts of the world probably differ as well.
Asia has a long history of NTM research, both 
clinical and fundamental. Tsukamura et al. have reported 
on pulmonary NTM infections in Japan dating back to 
the early 1970s (4). Yet because many studies were not 
reported in English, knowledge of the distribution of NTM 
species in Asia is limited. However, these data will enhance 
our understanding of NTM diversity between and within 
species and their association with NTM disease in humans. 
For this reason, we searched the literature on clinical NTM 
isolation and disease from different regions in Asia and 
compared our ﬁ  ndings with previously published data from 
other regions.
Literature Search
From March 2009 to December 2009, we searched 
PubMed (www.ncbi.nlm.nih.gov/pubmed) for English-
language articles about nontuberculous mycobacteria in 
Asia. The search strategy was as follows: “mycobacteria, 
atypical” [MeSH] AND “Asia” [MeSH] OR “atypical 
mycobacterium infections” [MeSH] AND “Asia” [MeSH]. 
We chose the term Asia to incorporate the following 
countries: Brunei, Cambodia, East Timor, Indonesia, 
Lao People’s Democratic Republic, Malaysia, Myanmar, 
Philippines, Singapore, Thailand, Vietnam, Bangladesh, 
Bhutan, India, China, Hong Kong, Japan, South Korea, 
Mongolia, and Taiwan.
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We found 256 citations. If we considered the abstract 
to be relevant, we obtained a full copy of the article; we 
contacted authors if full-text articles could not be retrieved. 
Furthermore, the reference sections were screened for 
other eligible citations. We considered 67 articles to be 
relevant, of which 37 were excluded for the following 
reasons: 11 were case reports, 7 referred to disseminated 
NTM infections, 6 were not in English (5 in Japanese, 1 
in Chinese), 6 did not concern pulmonary NTM, 4 were 
reviews, and 3 represented neither epidemiologic data nor 
clinical cases. From the remaining 30 articles (4–33), the 
following data were abstracted for this review: country, 
research setting, NTM species, clinical features of the 
patients, and radiographic data. All articles were screened 
to determine whether ATS diagnostic criteria for the 
determination of clinical relevance of NTM isolations 
applied (1). Cases consistent with the ATS diagnostic 
criteria were considered clinically relevant.
Search Results
We identiﬁ  ed 30 English-language articles about the 
epidemiology and clinical relevance of NTM isolates in 
Asia (4–33). We found data from China (5), Hong Kong 
(6), India (7–13), Japan (4,14–20), South Korea (21–24), 
Singapore (25), Taiwan (26–29), and Thailand (30–33). 
Most articles used a combination of methods to identify 
NTM species. Biochemical and phenotypic analysis (n = 
11) were used most frequently, followed by molecular tools 
(n = 4) or a combination of both (n = 5). From 10 articles, 
the exact methods of species identiﬁ  cation could not be 
determined. The use of identiﬁ  cation methods differed over 
time; biochemical and phenotypic analyses were mostly 
used during 1966–1990 (6 of 7 studies), whereas use of 
molecular tools increased during 1990–2009 (Table 1). The 
number of different species isolated did not differ between 
the 2 periods. However, most species identiﬁ  cation  by 
biochemical testing depended heavily on 1 study from 
India (11).
Epidemiology
Regardless of clinical relevance, 25 articles reported 
on NTM isolates from pulmonary samples (Figure 1) 
(4–13,17–22,25–33). In general, Mycobacterium avium 
complex (MAC) was most frequently (67%) isolated, 
although it predominated in northeastern Asia (South Korea 
and Japan). Exact species identiﬁ  cation of MAC (now M. 
avium, M. intracellulare, M. chimaera, M. colombiense, M. 
vulneris, M. marseillense, M. bouchedurhonense, and M. 
timonense) (34,35) was not performed, thereby hampering 
a more detailed analysis.
Rapidly growing mycobacteria ([RGM] M. fortuitum 
complex, M. abscessus, M. chelonae) were frequently 
identiﬁ   ed in pulmonary samples from Taiwan, China, 
and Singapore (5,25–29). The overall isolation of RGM 
in this part of Asia was 16%, making RGM the second 
most frequently isolated species in this region. Other 
species frequently encountered were M. kansasii (4%) and 
M. gordonae (3.5%). M. malmoense, a species regularly 
encountered in northwestern Europe, was found only 9 
times in a single study of 1,000 NTM isolates from India 
(11). Also, M. xenopi, which is frequently encountered in 
Canada and England (3), was isolated only 10 times (of 
11,987 isolates) and mainly during studies from India 
(7,11,13,21,27).
Clinical Relevance
The clinical relevance of pulmonary NTM isolates 
(Table 2) was mentioned in 10 articles covering a total of 
1,744 patients (6,16,21,23,25,28–30,32,33). No articles 
covered the clinical relevance of NTM in China. Different 
criteria were used to deﬁ   ne clinical relevance, but all 
criteria comprised a combination of clinical, bacteriologic, 
and radiographic criteria. Only 4 studies reported a priori 
use of ATS criteria (1). According to ATS criteria, for 31% 
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Table 1. Nontuberculous mycobacteria isolated in Asia, 1971–
2007*
Species
Before 1990  
(n = 1,205)† 
After 1990  
(n = 7,614)† 
Mycobacterium abscessus  –X
M. aichiense  X–
M. asiaticum  X–
M. avium complex  XX
M. celatum  –X
M. chelonae  XX
M. flavescens  XX
M. fortuitum  XX
M. gastri  XX
M. gordonae  XX
M hemophilum  X–
M. kansasii  XX
M. malmoense  X–
M. marinum  XX
M. neoarum  X–
M. parafortuitum  X–
M. phlei  XX
M. scrofulaceum  XX
M. simiae  XX
M. smegmatis  XX
M. szulgai  XX
M. terrae  XX
M. tokaiense  X–
M. triviale  XX
M. thermophilum  X–
M. thermoresistibile  X–
M. ulcerans  X–
M. vaccae  XX
M. xenopi  XX
*Data derived from references 4–33. X, isolated; –, not isolated. 
†Proportions of identification methods used (biochemical:molecular) 6:1 
before 1990, 5:8 after 1990.  Nontuberculous Mycobacteria in Respiratory Infections
(582/1,744) of patients, pulmonary NTM isolates were 
considered clinically relevant. Relevance varied widely 
across regions and studies. For example, a study of patients 
in an intensive care unit in Taiwan found that only 9% of 
NTM isolates were clinically relevant (28); however, in a 
study of HIV-infected patients in Thailand, relevance rose 
to 76% (30).
Figure 2 shows the distribution of mycobacterial 
species among patients with deﬁ   nite pulmonary NTM 
disease in Asia, according to ATS criteria. MAC was the 
most frequently reported (68% of all cases) cause of NTM 
disease; RGM were second (14% of all cases). Prevalence 
of RGM pulmonary infections ranged from 2.6% (Japan) 
to 44% (South Korea). M. malmoense and M. xenopi were 
not reported as causative species in any of these studies in 
Asia.
We found some discrepancies between isolation 
frequency (Figure 1) and clinical relevance (Figure 2). 
For example, in Hong Kong M. gordonae was found 
in 19% of pulmonary isolates regardless of clinical 
relevance but in only 4% of cases of pulmonary NTM 
infection. In contrast, in India, higher prevalence of M. 
szulgai was found (1% in all pulmonary samples vs. 
7% of all causes of pulmonary NTM). We therefore 
investigated the clinical relevance of the various NTM 
species separately, measuring clinical relevance per 
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India 
(n = 1,125) 
20% M. avium complex 
11% M. terrae 
10% M. scrofulaceum 
  7% M. flavescens 
  6% M. gordonae 
Thailand 
(n = 161) 
41% M. avium complex 
17% M. kansasii 
12% M. scofulaceum 
  6% M. fortuitum 
  4% M. gordonae 
China 
(n = 122) 
20% M. chelonae 
18% M. gordonae 
14% M. abscessus 
13% M. avium complex 
10% M. terrae 
Hong Kong 
(n = 168) 
19%     M. gordonae
15%     M. terrae 
12%     M. fortuitum 
   5%    M. chelonae 
   0.6% M. kansasii 
Singapore 
(n = 23) 
39% M. avium complex 
26% M. kansasii 
17% M. fortuitum 
  9% M. chelonae 
  4% M. abscessus 
Japan 
(n = 2,820) 
81%    M. avium complex 
10%    M. kansasii 
  3%    M. gordonae 
  3%    M. fortuitum 
  0.8% M. chelonae 
Taiwan 
(n = 440) 
42% M. avium complex 
18% M. abscessus 
13% M. chelonae 
11% M. kansasii 
 9% M. fortuitum 
South Korea 
(n = 7,128) 
73% M. avium complex 
  8% M. fortuitum 
  6% M. chelonae 
  3% M. gordonae 
2% M. kansasii
Figure 1. Five most prevalent nontuberculous 
mycobacteria species found in respiratory 
specimens, regardless of clinical relevance, Asia, 
1971–2007. Data from (4–13,17–22,25–33).
Table 2. Clinical relevance of NTM species isolated from pulmonary samples collected in Asia, by country, 1971–2007* 
Study area 
No.
patients
Patients for whom NTM 
infection was considered 
clinically relevant, %  Criteria used (year of revision)  Reference 
Hong Kong   168 17 ATS criteria (1990)  (6)
Japan 357 76† ATS criteria (1997)  (16)
South Korea  794 17 ATS criteria (1997)  (21)
South Korea  23 65‡ BTS criteria (1999)  (23)
Singapore  23 65 Compatible signs and symptoms, >3 positive sputum specimens, 
and radiographic features of recent lung disease 
(25)
Taiwan  111 9 ATS criteria (1990)  (28)
Taiwan  169 28§ NTM in >2 samples, new radiographic lesions ,and no other 
pathogens (definite) or other concomitant bacteria (probable NTM) 
found 
(29) 
Thailand 33 76 NTM in sample(s); compatible signs, symptoms, and radiographic 
features; and no other explanation 
(30)
Thailand 24 29 Continued NTM isolation, progressive pulmonary disease, and 
worsening radiographic lesions 
(32)
Thailand 42 71 Repeated isolation of high numbers of NTM and presence of 
compatible disease process 
(33)
*NTM, nontuberculous mycobacteria; ATS, American Thoracic Society (1); BTS, British Thoracic Society. 
†Only Mycobacterium avium complex bacteria were included in this study.  
‡Only M. kansasii was included. 
§14% if only definite NTM were included.SYNOPSIS
species by the percentage of patients meeting ATS criteria 
(Figure 3). Most clinically relevant species were MAC 
(56%), followed by M. abscessus (35%) and M. chelonae 
(31%). M. fortuitum, M. gordonae, and M. terrae were 
infrequently reported (1%–3%) as clinically relevant. 
The varying clinical relevance per species might partially 
explain the differences between Figure 1 and Figure 2.
Clinical Signs and Radiographic Features
We found information on clinical signs for 689 
patients and radiographic data for 1,044 patients (10,12,14–
16,20,21,23–25,27–30,33).  Most patients with pulmonary 
NTM infections were male (543/689). Because of 
incomplete data, mean age could not be calculated; 8 studies 
reported mean ages of 50–70 years. Other characteristics 
are shown in Table 3. One third of patients had a history 
of tuberculosis (TB) (252/689). HIV co-infection was 
less prevalent among patients with localized pulmonary 
NTM infections (15/280). Clinical signs of NTM disease 
mimicked those typical of TB: most frequently chronic 
cough (255/268), followed by hemoptysis (82/268), fever 
(47/268), and weight loss (40/268). Radiographically, most 
patients had structural lung disease; 39% (405/1,044) had 
cavitations and 44% (461/1,044) had bronchiectasis.
Discussion
NTM isolation and disease in Asia have several 
features. First, a substantial percentage (31%) of patients 
from whom pulmonary NTM were isolated had clinically 
relevant NTM disease. This ﬁ  nding is similar to the 33% 
and 25% found in studies in Canada and the Netherlands, 
respectively (2,3). In Asia, NTM may cause substantial 
pulmonary disease; differences in clinical relevance exist 
among species (Figure 3), as previously observed (2).
Second, MAC was the main cause of pulmonary NTM 
infection (68% of cases) in Asia. In a key article in 2002, 
Marras and Daley reviewed the prevalence of pulmonary 
NTM disease in the world (3). They noted a predominance 
of MAC among the causative agents of pulmonary NTM 
disease in Asia. Data from Asia were, however, scarce, 
and their conclusion was mainly based on 1 study (6). Our 
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India 
(n = 15) 
40% M. fortuitum 
33% M. kansasii 
20% M. triviale 
  7% M. szulgai
Thailand 
(n = 132) 
43% M. avium complex 
17% M. kansasii 
  8% M. scrofulaceum 
  5% M. fortuitum 
  5% M. chelonae 
Hong Kong 
(n = 28) 
54% M. avium complex
14% M. chelonae 
  4% M. kansasii 
  4% M.  szulgai 
  4% M. gordonae 
Singapore 
(n = 15) 
60% M. avium complex 
27% M. kansasii 
  7% M. chelonae 
  7% M. scrofulaceum 
Japan 
(n = 1,064) 
81%    M. avium complex 
14%    M. kansasii 
  2%    M. fortuitum 
  0.6% M. chelonae 
  0.5% M. szulgai 
Taiwan 
(n = 302) 
43% M. avium complex 
19% M. abscessus 
10% M. chelonae 
10% M. fortuitum 
 9% M. kansasii 
South Korea 
(n = 131) 
50% M. avium complex
39% M. abscessus 
  4% M. kansasii 
  3% M. fortuitum 
  2% M. chelonae 
Figure 2. Five most common nontuberculous 
mycobacteria species causing pulmonary 
infections, Asia, 1971–2007. Data from 
(4,6,10,13,17,19,21,25,27–33).
Table 3. Clinical and radiographic characteristics for patients with 
pulmonary nontuberculous mycobacteria infections in Asia, 
1971–2007* 
Characteristic No. (%) patients 
Concurrent conditions, n = 689 
  Malignancy, hematologic or solid  79 (11) 
  Gastrointestinal disease  40 (6) 
  HIV infection, n = 280 tested  15 (5) 
  Chronic corticosteroid treatment  18 (3) 
  Diabetes mellitus  18 (3) 
  Renal disease  13 (2) 
Previous lung disease, n = 689 
  Tuberculosis   252 (37) 
  Chronic obstructive pulmonary disease   62 (9) 
 Bronchiectasis  47  (7) 
Clinical signs, n = 268 
  Chronic cough  255 (95) 
 Hemoptysis  82  (31) 
 Fever  47  (18) 
  Weight loss  40 (15) 
Radiographic findings, n = 1,044 
 Cavitation  405  (39) 
 Nodular  559  (54) 
 Bronchiectasis  461  (44) 
*Data from (10,12,14–16,20,21,23–25,27–30,33).Nontuberculous Mycobacteria in Respiratory Infections
study supports their conclusion of the predominance of 
MAC in Asia, which is consistent with its predominance in 
other parts of the world, namely, North America and most 
parts of Europe (3).
Third, we found that in some regions in Asia, RGM 
are a major cause of pulmonary NTM disease. This ﬁ  nding 
contrasts with studies of NTM in other parts of the world 
(3). In a surveillance study from the Netherlands for 
instance, RGM caused only 3% of all pulmonary NTM 
infections (2). In the United States, this percentage is ≈5% 
(36). In the present review, RGM was found to generally 
cause 14% of pulmonary NTM infections, but in 3 
countries (India, Taiwan, South Korea) this percentage rose 
to >30% of infections. The fact that RGM were frequently 
found in pulmonary samples (Figure 1) could reﬂ  ect higher 
environmental exposure of RGM in Asia and, hence, higher 
isolation frequency. The predominance of RGM species 
may be the result of laboratory practices as well. Ethnic 
factors may also contribute to susceptibility to different 
species; i.e., Asian persons could be more susceptible to 
RGM infection.
Contrary to the high frequency of isolation of RGM 
species,  M. malmoense and M. xenopi, frequently seen 
in other parts of the world, were not seen as causative 
species in any of the studies from Asia. M. xenopi has 
been associated with hot water systems (1); as a result, it 
might be expected to be more rare in Asia, where the water 
delivery infrastructure is less developed than that in Europe 
and North America.
A fourth feature of pulmonary NTM disease in Asia—
compared with Europe and North America—was the 
relatively high percentage of patients with a history of TB. 
This ﬁ  nding might merely reﬂ  ect the higher incidence of 
TB in Asia, or it could reﬂ  ect higher clinician awareness 
in Asia, such that physicians order Mycobacterium spp. 
cultures in former TB patients with coughing and hence ﬁ  nd 
a relatively higher number of NTM isolates. Alternatively, 
it could reﬂ  ect a true predilection of NTM for patients 
with structural lung disease (1) associated with a higher 
susceptibility to mycobacterial infection in general. The 
role of TB in the pathogenesis of pulmonary NTM disease 
is controversial; structural lung damage by a TB infection 
renders the host vulnerable to NTM disease (1), but there 
are also clues that exposure to TB infers cross-protection to 
NTM disease (37).
Our study has some limitations. The major limitation 
is the language restriction. The inclusion of languages other 
than English would probably have increased precision. 
For instance, during our literature search we came across 
5 articles, published as abstracts in PubMed, on NTM 
infections in Japan. Although certain aspects of these data 
were already published in the English-language articles 
we included, we did not have the means to include these 
non–English-language studies. Nevertheless, our study 
illustrates the distribution of NTM infections from different 
geographic areas in Asia and will increase knowledge of 
the distribution and relevance of NTM species in Asia.
Another limitation is the long time span of the included 
studies. Because they ranged from 1969 to 2008, they 
used different decontamination, culture, and identiﬁ  cation 
methods. Data should therefore be considered with caution 
because of the variety of laboratory procedures used by the 
several authors to isolate and identify NTM. First, different 
sample decontamination protocols may determine the 
yield of NTM by selecting for certain NTM species and 
inhibiting others (38). Second, the introduction of more 
sensitive liquid media probably increased NTM isolation 
and perhaps selected for speciﬁ  c species (26). Finally, and 
foremost, the major differences in identiﬁ  cation methods 
used in the studies introduce important biases. Because 
the taxonomy of NTM has been changing in recent years 
(37,39,40), the different NTM identiﬁ  cation methods used 
in the various studies might have inﬂ  uenced our results; use 
of molecular tools to identify the historical isolates would 
probably result in different, more detailed, identiﬁ  cations, 
especially among the MAC, the M. simiae group, and the 
RGM (37,39,40). We did note increased use of molecular 
tools for NTM identiﬁ  cation over time (Table 1), which 
will, over the next few years, provide us with a more up-to-
date overview of NTM species distribution in Asia.
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
56%M.aviumcomplex (438/776)
35%M.abscessus(60/170)
31%M.chelonae(15/48)
17%M.kansasii (34/198)
M.scrofulaceum(6/35)
9%M.celatum (1/11)
6%M.szulgai (2/33)
3%M.fortuitum
(8/262)
2%M.
gordonae
(2/125)
1%M.terrae(1/75)
Figure 3. Clinical relevance of pulmonary nontuberculous 
mycobacterium (NTM) isolates, Asia, 1971–2007. Relevance per 
species was deﬁ   ned as percentage of patients with pulmonary 
NTM isolates meeting the American Thoracic Society criteria. 
Species reported infrequently, i.e., <5×, are not shown. Data from 
(6,16,17,21,23,25,29,32,33).SYNOPSIS
In conclusion, despite the limitations of language 
and species identiﬁ   cation methods, we have described 
the scale of human pulmonary NTM infections in eastern 
Asia. MAC bacteria were not only the most prevalent 
NTM found in pulmonary samples, but they were also the 
most common cause of pulmonary NTM disease in this 
geographic region. Distinct epidemiologic and clinical 
characteristics of pulmonary NTM disease in Asia were 
found: many patients had a history of TB, and RGM were 
a frequent cause of pulmonary NTM infections. These 
distinct characteristics of pulmonary NTM disease in this 
part of the world are not well reﬂ  ected in the current ATS 
criteria on NTM infections and could be incorporated in 
future guidelines.
Dr Simons is a resident in pulmonary medicine at the 
Radboud University Nijmegen Medical Centre. His primary 
research interest focuses on resistance mechanisms in multidrug-
resistant tuberculosis.
References
  1.   Grifﬁ  th DE, Aksamit T, Brown-Elliot BA, Catanzaro A, Daley C, 
Gordin F, et al. An ofﬁ  cial ATS/IDSA statement: diagnosis, treat-
ment and prevention of nontuberculous mycobacterial diseases. 
Am J Respir Crit Care Med. 2007;175:367–416. DOI: 10.1164/
rccm.200604-571ST
  2.   van Ingen J, Bendien SA, de Lange WC, Hoefsloot W, Dekhuijzen 
PN, Boeree MJ, et al. Clinical relevance of non-tuberculous myco-
bacteria isolated in the Nijmegen-Arnhem region, the Netherlands. 
Thorax. 2009;64:502–6. DOI: 10.1136/thx.2008.110957
  3.   Marras TK, Daley C. Epidemiology of human pulmonary infection 
with nontuberculous mycobacteria. Clin Chest Med. 2002;23:553–
67. DOI: 10.1016/S0272-5231(02)00019-9
  4.   Tsukamura M, Shimoide H, Kita N, Kawakami K, Ito T, Nakajima 
N, et al. Epidemiologic studies of lung disease due to mycobacte-
ria other than Mycobacterium tuberculosis in Japan. Rev Infect Dis. 
1981;3:997–1007.
  5.   Weimin L, Guanglu J, Zhihui L, Huakan H, Liquan C, Miao T, et 
al. Non-tuberculous mycobacteria in China. Scand J Infect Dis. 
2007;39:138–41. DOI: 10.1080/00365540600951234
  6.   Hosker HSR, Lam CW, Ng TK, Ma HK, Chan SL. The prevalence 
and clinical signiﬁ  cance of pulmonary infection due to non-tubercu-
lous mycobacteria in Hong Kong. Respir Med. 1995;89:3–8. DOI: 
10.1016/0954-6111(95)90063-2
 7.   Agarwal SK, Jamil Z, Srivasta VK, Rathi AK, Mehrotra L. A clin-
ico-bacteriological assessment of pulmonary tuberculosis patients 
with reference to drug resistance pattern in treated and untreated 
cases. Indian J Med Sci. 1980;34:39–46.
 8.   Choudri DS, Dube MK, Purohit SD, Dube S. The prevalence of 
anonymous mycobacteria in both resistant as well as fresh cases of 
pulmonary tuberculosis in the local population of south east Rajast-
han. Indian J Pathol Microbiol. 1979;22:165–75.
    9.    Jesudason MV, Gladstone P. Non tuberculous mycobacteria iso-
lated from clinical specimens at a tertiary care hospital in south 
India. Indian J Med Microbiol. 2005;23:172–5. DOI: 10.4103/0255-
0857.16589
10.   Karak K, Bhattacharyya S, Majumdar S, De PK. Pulmonary in-
fection caused by mycobacteria other than M. tuberculosis in and 
around Calcutta. Indian J Pathol Microbiol. 1996;39:131–4.
11.   Paramasivan CN, Govindan D, Prabhakar R, Somasundaram PR, 
Subbammal S, Tripathy SP. Species level identiﬁ   cation of non-
tuberculous mycobacteria from south Indian BCG trial area dur-
ing 1981. Tubercle. 1985;66:9–15. DOI: 10.1016/0041-3879(85)
90048-0
12.   Ramakrishnan CV. Pulmonary disease due to atypical mycobacte-
ria: a retrospective study from south India. Rev Infect Dis. 1981;3:
1090–2.
13.   Shanker SVR, Jain NK, Chandrasekhar S, Singh MM. Prevalence of 
atypical mycobacteria in sputum of patients undergoing treatment at 
a tuberculosis clinic. Indian J Chest Dis Allied Sci. 1989;31:9–13.
14.   Kobashi Y, Matsushima T. Comparison of clinical features in pa-
tients with pulmonary Mycobacterium-avium complex (MAC) dis-
ease treated before and after proposal for guidelines. J Infect Che-
mother. 2004;10:25–30. DOI: 10.1007/s10156-003-0273-3
15.   Kobashi Y, Matsushima T. The microbiological and clinical effects 
of combined therapy according to guidelines on the treatment of 
pulmonary Mycobacterium avium complex disease in Japan—in-
cluding a follow-up study. Respiration. 2007;74:394–400. DOI: 
10.1159/000095674
16.   Okumura M, Iwai K, Ogata H, Ueyama M, Kubota M, Aoki M, et 
al. Clinical factors on cavitary and nodular bronchiectatic types in 
pulmonary  Mycobacterium avium complex disease. Intern Med. 
2008;47:1465–72. DOI: 10.2169/internalmedicine.47.1114
17.   Saito H, Watanabe T, Akamatsu S, Yamamoto Y, Irikura T, Kuboni-
shi K, et al. Incidence of atypical mycobacteria and pulmonary my-
cobacterioses in national sanatoria in the Chugoku-Shikoku area. 
Hiroshima J Med Sci. 1979;28:161–5.
18.   Rapid increase of the incidence of lung disease due to Mycobac-
terium kansasii in Japan. Chest. 1983;83:890–2. DOI: 10.1378/
chest.83.6.890
19.   Tsukamura M, Kita N, Shimoide H, Arakawa H, Kuze A. Studies on 
the epidemiology of nontuberculous mycobacteriosis in Japan. Am 
Rev Respir Dis. 1988;137:1280–4.
20.   Yamamoto M. Pulmonary disease due to Mycobacterium szulgai 
in Japan. Intern Med. 2000;39:277–9. DOI: 10.2169/internalmedi-
cine.39.277
21.   Koh WJ, Kwon OJ, Jeon K, Kim TS, Lee KS, Park YK, et al. Clini-
cal signiﬁ  cance of nontuberculous mycobacteria isolated from respi-
ratory specimens in Korea. Chest. 2006;129:341–8. DOI: 10.1378/
chest.129.2.341
22.   Ryoo SW, Shin S, Shim MS, Park YS, Lew WJ, Park SN, et al. 
Spread of nontuberculous mycobacteria from 1992 to 2006 in Kore-
ans. J Clin Lab Anal. 2008;22:415–20. DOI: 10.1002/jcla.20278
23.  Yim JJ, Park YK, Lew WJ, Bai GH, Han SK, Shim YS. Mycobac-
terium kansasii pulmonary disease in Korea. J Korean Med Sci. 
2005;20:957–60. DOI: 10.3346/jkms.2005.20.6.957
24.   Yim JJ, Kim HJ, Kwon OJ, Koh WJ. Association between micro-
satellite polymorphisms in intron II of the human Toll-like recep-
tor 2 gene and nontuberculous mycobacterial lung disease in a Ko-
rean population. Hum Immunol. 2008;69:572–6. DOI: 10.1016/j.
humimm.2008.06.003
25.   Teo SK, Lo KL. Nontuberculous mycobacterial disease of the lungs 
in Singapore. Singapore Med J. 1992;33:464–6.
26.   Chien HP, Yu MC, WU MH, Lin TP, Luh KT. Comparison of the 
BACTEC MGIT 960 with Löwenstein-Jensen medium for recov-
ery of mycobacteria from clinical specimens. Int J Tuberc Lung Dis. 
2000;4:866–70.
27.   Ding LW, Lai CC, Lee LN, Hsueh PR. Disease caused by non-
tuberculous mycobacteria in a university hospital in Taiwan, 
1997–2003. Epidemiol Infect. 2006;134:1060–7. DOI: 10.1017/
S0950268805005698
28.   Shih JY, Hsueh PR, Lee LN, Wang HC, Yang PC, Kuo SH, et al. 
Nontuberculous mycobacteria isolates: clinical signiﬁ  cance and dis-
ease spectrum. J Formos Med Assoc. 1997;96:621–7.
348  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 3, March 2011Nontuberculous Mycobacteria in Respiratory Infections
29.   Shu CC, Lee CH, Wang JY, Jerng JS, Yu CJ, Hsueh PR, et al. Non-
tuberculous mycobacteria pulmonary infection in medical intensive 
care unit: the incidence, patient characteristics, and clinical sig-
niﬁ  cance. Intensive Care Med. 2008;34:2194–201. DOI: 10.1007/
s00134-008-1221-6
30.   Ratanasuwan W, Techasathit W, Chuenarom V, Suwanagool S, An-
ekthananont T, Jearanaisilavong J, et al. Infection due to nontuber-
culous Mycobacterium other than MAC in AIDS patients at Siriraj 
Hospital during 1998–2000: saphophyte vs pathogen. J Med Assoc 
Thai. 2002;85:886–93.
31.   Saritsiri S, Udomsantisook N, Suankratay C. Nontuberculous infec-
tions in King Chulalongkorn Memorial Hospital. J Med Assoc Thai. 
2006;89:2035–46.
32.   Sriyabhaya N, Wongwatana S. Pulmonary infection caused by atypi-
cal mycobacteria: a report of 24 cases in Thailand. Rev Infect Dis. 
1981;3:1085–9.
33.   Wongwatana S, Sriyabhaya N. Nontuberculous mycobacterial infec-
tion of the lung in a chest hospital in Thailand. J Med Assoc Thai. 
1992;75:1–10.
34.   van Ingen J, Boeree MJ, Kösters K, Wieland A, Tortoli E, Dekhui-
jzen PN, et al. Proposal to elevate Mycobacterium avium complex 
ITS sequevar MAC-Q to Mycobacterium vulneris sp. nov. Int J Syst 
Evol Microbiol. 2009;59:2277–82. DOI: 10.1099/ijs.0.008854-0
35.   Ben Salah I, Cayrou C, Raoult D, Drancourt M. Mycobacterium 
marseillense sp. nov., Mycobacterium timonense sp. nov., and My-
cobacterium bouchedurhonense sp. nov., members of the Mycobac-
terium avium complex. Int J Syst Evol Microbiol. 2009;59:2803–8. 
DOI: 10.1099/ijs.0.010637-0
36.   O’Brien RJ, Geiter LJ, Snider D. The epidemiology of nontubercu-
lous mycobacterial diseased in the United States. Am Rev Respir 
Dis. 1987;135:1007–14.
37.    Trnka L, Dankova D, Svandova E. Six years’ experience with 
the discontinuation of BCG vaccination: 4. Protective effect of 
BCG vaccination against the Mycobacterium avium intracellulare 
complex. Tuber Lung Dis. 1994;75:348–52. DOI: 10.1016/0962-
8479(94)90080-9
38.   Buijtels PC, Petit PL. Comparison of NaOH-n-acetyl cysteine and 
sulfuric acid decontamination methods for recovery of mycobacteria 
from clinical specimens. J Microbiol Methods. 2005;62:83–8. DOI: 
10.1016/j.mimet.2005.01.010
39.   Adékambi T, Colson P, Drancourt M. rpoB-based identiﬁ  cation of 
nonpigmented and late-pigmenting rapidly growing mycobacteria. J 
Clin Microbiol. 2003;41:5699–708. DOI: 10.1128/JCM.41.12.5699-
5708.2003
40.   Tortoli E. Impact of genotypic studies on mycobacterial tax-
onomy: the new mycobacteria of the 1990s. Clin Microbiol Rev. 
2003;16:319–54. DOI: 10.1128/CMR.16.2.319-354.2003
Address for correspondence: Sami Simons, Radboud University Medical 
Centre Nijmegen, Department of Pulmonary Diseases–454, PO Box 9101, 
6500 HB Nijmegen, the Netherlands; email: s.simons@long.umcn.nl
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 17, No. 3, March 2011  349
Use of trade names is for identiﬁ  cation only and does not 
imply endorsement by the Public Health Service or by the US 
Department of Health and Human Services.